Logo image of ITOS

ITEOS THERAPEUTICS INC (ITOS) Stock Fundamental Analysis

NASDAQ:ITOS - Nasdaq - US46565G1040 - Common Stock - Currency: USD

7.35  -0.11 (-1.47%)

After market: 7.35 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ITOS. ITOS was compared to 567 industry peers in the Biotechnology industry. ITOS has a great financial health rating, but its profitability evaluates not so good. ITOS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ITOS has reported negative net income.
In the past year ITOS has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ITOS reported negative net income in multiple years.
In the past 5 years ITOS reported 4 times negative operating cash flow.
ITOS Yearly Net Income VS EBIT VS OCF VS FCFITOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

ITOS has a better Return On Assets (-19.57%) than 79.37% of its industry peers.
ITOS has a better Return On Equity (-22.77%) than 84.48% of its industry peers.
Industry RankSector Rank
ROA -19.57%
ROE -22.77%
ROIC N/A
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ITOS Yearly ROA, ROE, ROICITOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

ITOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ITOS Yearly Profit, Operating, Gross MarginsITOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

ITOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ITOS has more shares outstanding
The number of shares outstanding for ITOS has been increased compared to 5 years ago.
ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ITOS Yearly Shares OutstandingITOS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ITOS Yearly Total Debt VS Total AssetsITOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ITOS has an Altman-Z score of 1.83. This is not the best score and indicates that ITOS is in the grey zone with still only limited risk for bankruptcy at the moment.
ITOS's Altman-Z score of 1.83 is fine compared to the rest of the industry. ITOS outperforms 71.60% of its industry peers.
ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.83
ROIC/WACCN/A
WACC10.2%
ITOS Yearly LT Debt VS Equity VS FCFITOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

ITOS has a Current Ratio of 12.62. This indicates that ITOS is financially healthy and has no problem in meeting its short term obligations.
ITOS's Current ratio of 12.62 is amongst the best of the industry. ITOS outperforms 85.54% of its industry peers.
A Quick Ratio of 12.62 indicates that ITOS has no problem at all paying its short term obligations.
The Quick ratio of ITOS (12.62) is better than 85.54% of its industry peers.
Industry RankSector Rank
Current Ratio 12.62
Quick Ratio 12.62
ITOS Yearly Current Assets VS Current LiabilitesITOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

ITOS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.71%.
The Revenue has grown by 177.78% in the past year. This is a very strong growth!
Measured over the past years, ITOS shows a very negative growth in Revenue. The Revenue has been decreasing by -53.35% on average per year.
EPS 1Y (TTM)-5.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.18%
Revenue 1Y (TTM)177.78%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.45% on average over the next years. This is quite good.
ITOS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.00% yearly.
EPS Next Y-23.31%
EPS Next 2Y-15.2%
EPS Next 3Y-6%
EPS Next 5Y13.45%
Revenue Next Year-83.85%
Revenue Next 2Y-53.88%
Revenue Next 3Y-25.99%
Revenue Next 5Y27%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ITOS Yearly Revenue VS EstimatesITOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ITOS Yearly EPS VS EstimatesITOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ITOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ITOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ITOS Price Earnings VS Forward Price EarningsITOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITOS Per share dataITOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as ITOS's earnings are expected to decrease with -6.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.2%
EPS Next 3Y-6%

More info and screens

0

5. Dividend

5.1 Amount

ITOS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ITEOS THERAPEUTICS INC

NASDAQ:ITOS (4/25/2025, 8:16:26 PM)

After market: 7.35 0 (0%)

7.35

-0.11 (-1.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05 2025-03-05/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners95.31%
Inst Owner Change-57.24%
Ins Owners0.92%
Ins Owner Change5.61%
Market Cap280.70M
Analysts85
Price Target25.7 (249.66%)
Short Float %4.85%
Short Ratio4.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.35%
Min EPS beat(2)-15.79%
Max EPS beat(2)5.09%
EPS beat(4)3
Avg EPS beat(4)22.2%
Min EPS beat(4)-15.79%
Max EPS beat(4)82.99%
EPS beat(8)7
Avg EPS beat(8)25.01%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.95%
PT rev (3m)0.8%
EPS NQ rev (1m)-2.12%
EPS NQ rev (3m)26.78%
EPS NY rev (1m)-3.37%
EPS NY rev (3m)4.74%
Revenue NQ rev (1m)-20%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)10.54%
Revenue NY rev (3m)10.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.02
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB 0.48
EV/EBITDA N/A
EPS(TTM)-3.33
EYN/A
EPS(NY)-4.11
Fwd EYN/A
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.57
OCFYN/A
SpS0.92
BVpS15.46
TBVpS15.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.57%
ROE -22.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 133.93%
Cap/Sales 4.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.62
Quick Ratio 12.62
Altman-Z 1.83
F-Score4
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)204.25%
Cap/Depr(5y)178.55%
Cap/Sales(3y)9.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.18%
EPS Next Y-23.31%
EPS Next 2Y-15.2%
EPS Next 3Y-6%
EPS Next 5Y13.45%
Revenue 1Y (TTM)177.78%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-83.85%
Revenue Next 2Y-53.88%
Revenue Next 3Y-25.99%
Revenue Next 5Y27%
EBIT growth 1Y-5.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.37%
OCF growth 3YN/A
OCF growth 5YN/A